share_log

Financial Contrast: Zenvia (NASDAQ:ZENV) & Definitive Healthcare (NASDAQ:DH)

Defense World ·  Dec 31, 2022 01:11

Definitive Healthcare (NASDAQ:DH – Get Rating) and Zenvia (NASDAQ:ZENV – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Definitive Healthcare and Zenvia, as provided by MarketBeat.

Get Definitive Healthcare alerts:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definitive Healthcare 0 5 4 0 2.44
Zenvia 0 4 0 0 2.00

Definitive Healthcare presently has a consensus target price of $19.11, indicating a potential upside of 73.90%. Zenvia has a consensus target price of $2.63, indicating a potential upside of 128.26%. Given Zenvia's higher probable upside, analysts plainly believe Zenvia is more favorable than Definitive Healthcare.

Valuation & Earnings

This table compares Definitive Healthcare and Zenvia's top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Definitive Healthcare $166.15 million 6.95 -$51.02 million ($0.27) -40.70
Zenvia $113.49 million 0.42 -$8.27 million ($0.25) -4.60

Zenvia has lower revenue, but higher earnings than Definitive Healthcare. Definitive Healthcare is trading at a lower price-to-earnings ratio than Zenvia, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

35.7% of Zenvia shares are owned by institutional investors. 17.5% of Definitive Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Definitive Healthcare and Zenvia's net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Definitive Healthcare -12.56% 0.69% 0.49%
Zenvia -5.59% -3.71% -2.36%

Risk & Volatility

Definitive Healthcare has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Zenvia has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

About Definitive Healthcare

(Get Rating)

Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution. The company's platform offers 16 intelligence modules that cover functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate companies, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.

About Zenvia

(Get Rating)

Zenvia Inc. provides customer experience communications platform which empowers businesses to create unique journeys for their end-customers along their life cycle across range of B2C verticals. Zenvia Inc. is based in S?O PAULO.

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment